ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Affiris Uses Definiens Technology In Fight Against Alzheimer's Disease
Affiris GmbH
announced today that it will integrate the Definiens Enterprise Image
Intelligence (TM) Suite in the company's Alzheimer's disease vaccination
program. The decision was based on the company's outstanding experience with
Definiens software. Affiris' business strategy focuses on rapid
identification of drug candidates and accelerated preclinical and clinical
development. Matching Affiris requirements comprehensively, Definiens
provides automated image analysis solutions with reliable, fast and
consistent results.
DEFINIENS ¬ UNPARALLELED IMAGE ANALYSIS COUPLED WITH TIME AND COST SAVING
In order to launch its new AFFITOPETM vaccines, which facilitate the
induction of a desired antibody immune response, Affiris wants to streamline
its processes and control timelines more aggressively. One bottleneck common
in preclinical stages is the detailed analysis of a large amount of high
content images. In the project the challenge was automating high content
image analysis of histological slides of mouse brains. Crucial factors were
the batch processing and job scheduling capabilities of the Definiens
software which enable efficient processing of files larger than 1 GB.
Definiens' automated image analysis will not only help Affiris to reduce
costs and save its scientific personnel time, but the results will also be
more objective compared to a manual approach.
PEPTIDE-BASED VACCINES AGAINST ALZHEIMER'S DISEASE
In November 2007 Affiris attracted public attention, when it was granted a
European-wide patent for key elements of its Alzheimer's disease vaccination
strategy. The hallmark of Alzheimer's disease are deposits of aggregated
beta-amyloid peptide in the brain. Beta-amyloid is removed from larger
precursor protein by the body's own enzymes, in healthy as well as afflicted
persons. It is generally believed however, that in Alzheimer's disease the
regulation of this removal is disturbed, leading to higher amounts and/or
more aggregation-prone species of beta-amyloid. AFFITOPETM vaccines,
invented and produced by Affiris, are modified beta-amyloid-like peptides
which elicit an immune response against the aggregation-prone beta-amyloid,
but not against the physiological precursor protein. One such vaccine is
currently undergoing clinical tests, while others are still in the
preclinical stage.
Dr. Markus Mandler, Head of Neurodegeneration Department at Affiris, said
"The Definiens Enterprise Image Intelligence Suite is an open platform that
can be easily integrated with the existing hardware as well as image
acquisition devices and software. It enables even untrained users to
calibrate and execute versatile image analysis workflows. Thanks to the
user-friendliness of the platform and the excellent support provided by
Definiens, the implementation process will be very short and the technology
is expected to become part of our work routine as early as February 2008."
About AFFiRiS
AFFiRiS GmbH develops peptide-based vaccines for the treatment of
Alzheimer's disease, atherosclerosis and other serious diseases. The company
has established its AFFITOME platform technologies. It employs 30 highly
qualified members of staff on 600 sqm of rented laboratory facilities at the
Campus Vienna Biocenter (http://www.affiris.com).
AFFITOPE and AFFITOME are registered trademarks of Affiris GmbH.
Definiens in Life Sciences
By automating image analysis on an enterprise level, Definiens supports Life
Science organizations to analyze and interpret vast numbers of images
accurately and consistently. Definiens improves the measurement of cell
assays, the examination of tissue samples and the interpretation of
non-invasive imaging, enabling high-content screening, digital pathology and
translational medicine.
About Definiens
Definiens is the number one Enterprise Image Intelligence company for
analyzing and interpreting images on every scale, from microscopic cell
structures to satellite images. The Definiens Cognition Network Technology®,
developed by Nobel laureate Prof. Gerd Binnig and his team, is an advanced
and robust context-based technology designed to fulfill the image analysis
requirements of the Life and Earth sciences markets. The technology is
modeled on the powerful human cognitive perception processes to extract
intelligence from images. Definiens provides organizations with faster image
analysis results, allowing deeper insights enabling better business
decisions. The company is headquartered in Munich, Germany and has offices
throughout the United States. Further information is available at
http://www.definiens.com
Definiens, Definiens Cellenger, Definiens Cognition Network Technology,
Definiens eCognition, Enterprise Image Intelligence and Understanding Images
are trademarks or registered trademarks of Definiens.
Affiris foloseste tehnologie Definiens în lupta împotriva Boala Alzheimer - Affiris Uses Definiens Technology In Fight Against Alzheimer's Disease - articole medicale engleza - startsanatate